United Kingdom· GB-APID-45386311000001104
Guanfacine 2mg modified-release tablets
A guanfacine product containing guanfacine, registered in United Kingdom by Neuraxpharm UK Ltd. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Guanfacine is registered in 14 of 19 countries.
Countries holding a registration under ATC C02AC02 (guanfacine), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Guanfacine · ATC C02AC02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of guanfacine costs, country by country.
Normalised to the WHO defined daily dose (3 mg), the median price runs from $0.21 in United States to $7.74 in Switzerland — a ×37 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Guanfacine · price per daily dose (3 mg)
USD · FX 28 Sept 2026
- CH Switzerland$7.74
- US United States$0.21 (acquisition cost)
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Guanfacine
- Manufacturer
- Neuraxpharm UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- C02AC02
- ATC class
- Guanfacine
- Defined daily dose
- 3 mg, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin8436027473732
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
163 interactions on record for guanfacine.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Guanfacine · interactions on record
163 records
- 30 severe
- 133 moderate
Most severe, free to view
- AprepitantA04AD12severe
- DexamethasoneH02AB02severe
- KetoconazoleH02CA03severe
- ChloramphenicolJ01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Guanfacine in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesguanfacineActavis Pharma, Inc.
- CzechiaINTUNIVTakeda Pharmaceuticals International AG Ireland Branch, Dublin
- CanadaAPO-GUANFACINE XRAPOTEX INC
- IcelandIntunivTakeda Pharmaceuticals International AG Ireland Branch
- NetherlandsIntuniv 2 mg tabletten met verlengde afgifteTakeda Pharmaceuticals International AG Ireland Branch
- NorwayIntunivTakeda Pharmaceuticals International AG Ireland Branch
- PolandIntunivTakeda Pharmaceuticals International AG
- SwedenIntuniv 2 mg DepottablettTakeda Pharmaceuticals International AG Ireland Branch
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Germany · Guanfacin Neuraxpharm
- Iceland · Intuniv, Paxneury
- Liechtenstein · Intuniv, Paxneury
- Norway · Intuniv, Paxneury
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7cd37ef0-a483-4695-9095-7a8d8435f8ea GET /v1/drugs/7cd37ef0-a483-4695-9095-7a8d8435f8ea?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "45386311000001104",
"desc": "Guanfacine 2mg modified-release tablets (Neuraxpharm UK Ltd)",
"form": "Modified-release tablet",
"vpid": "31087711000001100",
"source": "dmd",
"vtm_id": "776162002",
"strength": "2 mg",
"substance": "Guanfacine",
"ingredient": "Guanfacine hydrochloride",
"supplier_code": "37898411000001108"
}See everything about guanfacine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.